Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia
- 5 December 2006
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 109 (8), 3219-3224
- https://doi.org/10.1182/blood-2006-09-045625
Abstract
The natural history of EBV and CMV reactivation and the potential for serious complications following antibody-based immunosuppressive treatment for bone marrow failure syndromes in the absence of transplantation is not known. We monitored blood for EBV and CMV reactivation by polymerase chain reaction (PCR) weekly in 78 consecutive patients (total of 99 immunosuppressive courses) with aplastic anemia. Four regimens were studied: (1) HC, horse ATG/cyclosporine; (2) HCS, horse ATG/CsA/sirolimus; (3) RC, rabbit ATG/CsA; and (4) CP, alemtuzumab. There were no cases of EBV or CMV disease, but EBV reactivation occurred in 82 (87%) of 94 and CMV reactivation in 19 (33%) of 57 seropositive patients after starting immunosuppression. The median peak EBV copies were higher in the RC group when compared with HC, HCS, and alemtuzumab (P < .001). The median duration of PCR positivity for EBV was higher in the RC group compared with HC, HCS, and alemtuzumab (P = .001). Subclinical reactivation of both EBV and CMV is common and nearly always self-limited in patients with bone marrow failure receiving immunosuppression; different regimens are associated with different intensity of immunosuppression as measured by viral load and lymphocyte count; and viral reactivation patterns differ according to immunosuppressive regimens.Keywords
This publication has 40 references indexed in Scilit:
- Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantationBlood, 2006
- Current concepts in the pathophysiology and treatment of aplastic anemiaBlood, 2006
- Latency‐associated human cytomegalovirus glycoprotein N genotypes in monocytes from healthy blood donorsTransfusion, 2006
- High Fatality Rate of Epstein-Barr Virus-Associated Lymphoproliferative Disorder Occurring after Bone Marrow Transplantation with Rabbit Antithymocyte Globulin Conditioning RegimensJournal of Clinical Microbiology, 2005
- Increased incidence of EBV‐related disease following paediatric stem cell transplantation with reduced‐intensity conditioningBritish Journal of Haematology, 2005
- Impaired recovery of Epstein-Barr virus (EBV)—specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative diseaseBlood, 2003
- Pre-emptive therapy with rituximab for prevention of Epstein–Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantationBone Marrow Transplantation, 2003
- Role of Cytotoxic T Lymphocytes in Epstein-Barr Virus-Associated DiseasesAnnual Review of Microbiology, 2000
- The development of B-cell lymphoma in a patient with psoriasis treated with cyclosporineJournal of the American Academy of Dermatology, 1992
- Primary Infection by Epstein–Barr Virus Presenting as Aplastic AnemiaThe New England Journal of Medicine, 1983